

Supplementary Materials

Emma Sandberg¹, Luís Nunes¹, Per-Henrik Edqvist¹, Lucy Mathot¹, Lei Chen^{1,2}, Tomas Edgren², Shahed Al Nassralla¹, Bengt Glimelius¹, Ulf Landegren^{1,*} and Tobias Sjöblom^{1,*}

¹ Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden; emma.sandberg@igp.uu.se (E. S); luis.nunes@igp.uu.se (L. N); per-henrik.edqvist@igp.uu.se (P-H. E); lucy.mathot@igp.uu.se (L. M); lei.chen@raritybioscience.com (L. C); shahed.alnassralla.9832@student.uu.se (S. A); bengt.glimelius@igp.uu.se (B. G); tomas.edgren@raritybioscience.com (T. E)

² Rarity Bioscience AB, SE-752 37 Uppsala, Sweden

* Correspondence: tobias.sjoblom@igp.uu.se (T. S); ulf.landegren@igp.uu.se (U. L)

Table S1. The superRCA CRC Mutation assay target panel.

Gene	Amplicon ID	Mutation			
KRAS	KRAS12	p.G12E (c.35_56delinsAG) p.G12C (c.34G>T) p.G12R (c.34G>C) p.G12S (c.34G>A) p.G12A (c.35G>C) p.G12D (c.35G>A) p.G12V (c.35G>T) p.G13C (c.37G>T) p.G13R (c.37G>C) p.G13D (c.38G>A)			
		KRAS61	p.A59T (c.175G>A) p.Q61L (c.182A>T) p.Q61H (c.183A>T) p.Q61H (c.183A>C)		
			KRAS146	p.A146T (c.436G>A) p.K147Q (c.439A>C) p.A146V (c.437C>T)	
NRAS	NRAS12			p.G12C (c.34G>T) p.G12R (c.34G>C) p.G12S (c.34G>A) p.G12A (c.35G>C) p.G12D (c.35G>A) p.G12V (c.35G>T) p.G13R (c.37G>C) p.G13D (c.38G>A) p.G13V (c.38G>T)	
				NRAS61	p.A59T (c.175G>A) p.Q61K (c.181C>A) p.Q61R (c.182A>G) p.Q61L (c.182A>T) p.Q61H (c.183A>C) p.Q61H (c.183A>T)
		PIK3CA	PIK3CA112		p.I112F (c.334A>T)

		p.K111E (c.331A>G)
	PIK3CA545	p.E542K (c.1624G>A) p.E545K (c.1633G>A) p.E545G (c.1634A>G) p.Q546K (c.1636C>A)
	PIK3CA1047	p.M1043I (c.3129G>T) p.H1047R (c.3140A>G) p.H1047L (c.3140A>T)
<i>BRAF</i>	BRAF600	p.V600E (c.1799T>A) p.V600K (c.1798_1799 GT>AA)
<i>AKT1</i>	AKT1	p.E17K (c.49G>A)

14

15

Table S2. Mutant allele frequencies of hotspot mutations *a priori* known in tumor and normal gDNA by superRCA. gDNA, genomic DNA; MAF, mutant allele frequencies.

Patient ID	Hotspot Mutation	Tumor gDNA MAF	Normal gDNA MAF
UU001	<i>KRAS</i> p.G13D	0.4486	1.950×10^{-6}
	<i>PIK3CA</i> p.E542K	0.1314	6.498×10^{-6}
UU002	<i>KRAS</i> p.G12D	0.4869	3.855×10^{-5}
UU003	<i>KRAS</i> p.G12V	0.5072	7.978×10^{-5}
	<i>PIK3CA</i> p.E545K	0.0001	3.511×10^{-6}
UU008	<i>KRAS</i> p.A146V	0.3145	6.895×10^{-6}
UU009	<i>BRAF</i> p.V600E	0.2633	7.633×10^{-6}
UU010	<i>KRAS</i> p.G12D	0.2548	7.806×10^{-5}
UU011	<i>KRAS</i> p.G12E	0.3652	2.869×10^{-6}
UU012	<i>BRAF</i> p.V600E	0.1522	1.062×10^{-5}
UU014	<i>BRAF</i> p.V600E	0.1303	5.224×10^{-5}
UU015	<i>BRAF</i> p.V600E	0.2604	5.753×10^{-5}
	<i>PIK3CA</i> p.H1047R	0.0025	6.560×10^{-5}
UU017	<i>BRAF</i> p.V600E	0.2741	6.925×10^{-6}
UU018	<i>KRAS</i> p.G13D	0.3779	8.641×10^{-5}
UU025	<i>NRAS</i> p.G12D	0.2927	3.279×10^{-5}
UU036	<i>BRAF</i> p.V600E	0.4539	2.089×10^{-4}
UU038	<i>PIK3CA</i> p.E542K	0.0003	3.858×10^{-5}

16
17

18

19

20

21

22

23

24

25

26

27

28

Table S3. Mutant allele frequencies of hotspot mutations determined by superRCA in plasma cell-free DNA at diagnosis, postoperatively and follow-up. MAF, mutant allele frequencies. N/A; Not Applicable.

Patient ID	Hotspot Mutations	Diagnosis Plasma		Postoperative Plasma		Follow-up Plasma			
		DNA input (ng)	MAF	DNA input (ng)	MAF	DNA input (ng)	MAF	DNA input (ng)	MAF
UU001	<i>KRAS</i> p.G13D	35.69	1.5541×10^{-2}	N/A	N/A	27.00	9.652435×10^{-2}	18.00	1.4992918×10^{-1}
UU001	<i>PIK3CA</i> p.E542K	35.69	2.865×10^{-3}	N/A	N/A	27.00	2.17358×10^{-2}	18.00	5.616191×10^{-2}
UU002	<i>KRAS</i> p.G12D	32.72	5.040×10^{-3}	N/A	N/A	16.20	2.9701×10^{-6}	12.30	6.1279×10^{-6}
UU003	<i>KRAS</i> p.G12V	12.83	1.2092×10^{-2}	N/A	N/A	8.38	5.4617×10^{-6}	12.60	5.7408×10^{-6}
UU003	<i>PIK3CA</i> p.E545K	12.83	1.1×10^{-5}	N/A	N/A	8.38	2.8563×10^{-6}	12.60	3.2439×10^{-6}
UU004	<i>KRAS</i> p.G12V	15.26	1.680×10^{-3}	8.18	7.44464×10^{-3}	9.83	6.80364×10^{-3}	N/A	N/A
UU008	<i>KRAS</i> p.A146V	16.52	1.456×10^{-3}	9.83	1.1264×10^{-5}	18.30	6.758×10^{-6}	N/A	N/A
UU009	<i>BRAF</i> p.V600E	19.31	3.4561×10^{-2}	N/A	N/A	10.50	3.0716×10^{-6}	17.70	1.62×10^{-5}
UU010	<i>KRAS</i> p.G12D	29.03	2.930×10^{-3}	N/A	N/A	13.20	1.3208×10^{-5}	30.60	4.5509×10^{-6}
UU011	<i>KRAS</i> p.G12E	29.03	1.551×10^{-3}	16.80	1.911×10^{-6}	10.50	4.5968×10^{-6}	N/A	N/A
UU012	<i>BRAF</i> p.V600E	38.70	1.725×10^{-3}	N/A	N/A	11.64	3.821×10^{-6}	21.30	7.1307×10^{-6}
UU014	<i>BRAF</i> p.V600E	21.29	2.032×10^{-3}	11.48	4.7223×10^{-6}	21.60	5.794×10^{-6}	N/A	N/A
UU015	<i>BRAF</i> p.V600E	18.45	1.4×10^{-5}	N/A	N/A	27.00	6.9854×10^{-6}	12.00	5.4248×10^{-6}
UU015	<i>PIK3CA</i> p.H1047R	18.45	1.830×10^{-3}	N/A	N/A	27.00	5.4652×10^{-6}	12.00	9.0385×10^{-6}
UU017	<i>BRAF</i> p.V600E	25.25	3.7850×10^{-2}	N/A	N/A	50.10	7.6084×10^{-6}	37.80	4.0263×10^{-6}
UU018	<i>KRAS</i> p.G13D	19.58	5.532×10^{-3}	N/A	N/A	13.80	2.8137×10^{-6}	23.40	3.4004×10^{-6}
UU020	<i>KRAS</i> p.G12D	32.09	3.60×10^{-4}	N/A	N/A	20.40	1.0193×10^{-5}	20.70	2.2713×10^{-6}
UU025	<i>NRAS</i> p.G12D	35.70	1.136×10^{-3}	N/A	N/A	32.10	3.9785×10^{-6}	26.70	4.1889×10^{-6}
UU035	<i>KRAS</i> p.G12V	13.50	4.689×10^{-3}	N/A	N/A	33.0	3.0094103×10^{-1}	N/A	N/A
UU036	<i>BRAF</i> p.V600E	16.50	5.80×10^{-4}	27.00	1.0387×10^{-5}	15.90	3.738×10^{-6}	N/A	N/A
UU037	<i>KRAS</i> p.G13C	N/A	N/A	24.00	1.0×10^{-5}	18.00	9.7298×10^{-4}	23.40	4.460193×10^{-2}
UU037	<i>PIK3CA</i> p.H1047L	N/A	N/A	24.00	3.0×10^{-6}	18.00	1.4937×10^{-3}	23.40	2.544395×10^{-2}
UU038	<i>PIK3CA</i> p.E542K	22.80	7.0×10^{-6}	N/A	N/A	27.00	6.8573×10^{-6}	30.90	7.877×10^{-6}

29
30
31

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50




Figure S1. Days from surgery to diagnosis, postoperative and follow-up plasma samples for all 25 patients and days to recurrent disease for applicable patients. UU004 did not have surgery, hence time points are from diagnosis.

51

52

53




Figure S2. Total cell-free DNA input for plasma samples at diagnosis, postoperatively and during follow-up.

54
55
56